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Abstract
Background: Vacation can present a major problem to patients with rheumatoid arthritis (RA) treated with weekly
subcutaneous biologics, including subcutaneous (SC) abatacept. Therefore, the replacement of four SC doses of
abatacept by a single dose of intravenous (IV) abatacept may present an acceptable alternative to cover a 4-week
interval needed for vacations. In the study presented, we analyzed the efficacy and safety of this intervention
followed by a switch back to SC abatacept after 4 weeks.
Method: This open-label, prospective, single-arm, 24-week trial recruited patients with established RA in low
disease activity (LDA) or in remission on treatment with SC abatacept for at least 3 months to receive a single dose
of IV abatacept (baseline) followed by a break of 4 weeks and then continuation of weekly SC abatacept from day
28 on. Disease-modifying anti-rheumatic drug (DMARD)-inadequate or biologic-inadequate responders (or both)
were included.
Results: The baseline characteristics of the 49 patients (per protocol) were typical for a cohort of RA patients with
established disease (mean disease duration of 8.31 years) in LDA under treatment with synthetic DMARDs and a
biologic. Two patients (one flare and one patient decision) dropped out of the study. The proportions of patients
with disease activity score in 28 joints (DAS-28) of not more than 3.2 at day 28 were 93.9 % (95 % confidence
interval (CI) 83.5–97.9) and 93.6 % (95 % CI 82.8–97.8) at the end of the study (day 168). The average DAS-28 values
were 1.74 (standard deviation (SD) ± 0.72) at baseline, 2.03 (SD ± 1.03) at day 28, and 1.96 (SD ± 0.92) at the end of
the study (day 168). Pre-exposure to IV abatacept and having failed methotrexate or anti-tumor necrosis factor
(anti-TNF) did not influence the average DAS-28 or the proportion of patients maintaining LDA over time. The
average health assessment questionnaire disability index (HAQ-DI) was stable throughout the study. Adverse events
(AEs) occurred in 75 % of subjects. Four serious AEs were described during the study. None of them was related to
the investigational product, and all serious AEs could be resolved during hospitalization.
Conclusion: This prospective, open-label study of abatacept shows for the first time that switching from weekly SC
to IV abatacept and back after 4 weeks is an effective and safe way to bridge vacations in RA patients in LDA or
remission. (NCT1846975, registered April 19, 2013.)
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease. With the introduction of biologic
disease-modifying anti-rheumatic drugs (DMARDs) more
than a decade ago [1], the options for the treatment of RA
have significantly improved. Biologic DMARDs (biologics)
can be categorized by their different mechanisms of action
and by the kind of application: subcutaneous (SC) or
intravenous (IV). Abatacept is able to induce symptom re-
duction and to delay the progression of structural damage
[2] in patients with RA. It was the first biologic to be avail-
able in both an SC [3] and an IV [4] formulation.
The efficacy and safety of IV abatacept have been well
established in recent years [5]. Moreover, clinical trials
comparing SC abatacept with IV abatacept have clearly
demonstrated a similar efficacy [2] and safety [6] profile.
A temporary withdrawal of SC abatacept for 3 months, in
RA patients methotrexate-inadequate response (MTX-IR),
however, resulted in increasing disease activity score in 28
joints (DAS-28) scores [7], which, in turn, decreased again
after reintroduction of the drug. Switching from IV to SC
abatacept appears to be associated with a persisting good
efficacy of abatacept and no increase in the rate of adverse
events (AEs) [8]. On the other hand, switching from SC to
IV abatacept has not been investigated in a clinical trial
setting so far.
Vacations may cause problems for patients with RA
treated with SC biologics, because transportation of the
biologics may be complicated for various reasons such
as customs regulations, maintenance of the cold chain,
or fragility of vials/syringes in the luggage. This is also
true for SC abatacept with its weekly application sched-
ule. In contrast to the weekly SC application, IV abata-
cept has to be administered only once every 4 weeks, a
time period covering most vacations. Thus, to avoid is-
sues just mentioned, patients under therapy with SC
abatacept may receive a single infusion of IV abatacept
before starting their vacation and will continue with SC
therapy 4 weeks later once they have returned back
home.
The objective of this open-label prospective study was
to determine whether replacing the mandatory regular
schedule of weekly SC injections of abatacept for 4 weeks
by a single IV infusion is a safe and effective treatment
for maintaining RA patients, who already reached a good
disease status on SC abatacept, such as DAS-28-defined
low disease activity (LDA) or remission.
Methods
Patients and study design
The A-BREAK (Abatacept Study to Omit Weekly Subcuta-
neous Injections in RA patients During Holiday BREAK)
study was a 24-week prospective, phase IV, open-label,
multi-center, single-arm clinical trial. Patients were all
switched from SC (125 mg/week) to IV abatacept (dosage
for body weight of less than 60 kg: 500 mg, 60–100 kg:
750 mg, and more than 100 kg: 1000 mg abatacept) at day
zero and switched back to SC abatacept (125 mg/week) at
day 28. All patients were followed until day 168. Concomi-
tant treatment with synthetic DMARDs (csDMARDs) was
mandatory. The study was conducted in accordance with
good clinical practice and the Declaration of Helsinki and
was approved by an institutional review committee at each
participating center (Ethikkommission des Kantons St.
Gallen, Ethikkommission Nordwest- und Zentralschweiz,
kantonalen Ethikkommission Bern, Ethikkommission des
Kantons Waadt, and Swissmedic). All participating patients
provided written informed consent (NCT1846975).
Participants
Eligible patients were diagnosed with RA, as defined by
the American College of Rheumatology/European League
Against Rheumatism 2010 criteria [9], of more than
3 months’ duration as of the date of inclusion. Effective
control of disease activity at baseline as defined by a DAS-
28 (erythrocyte sedimentation rate, or ESR) of not more
than 3.2 (LDA) was a prerequisite, and double-method
contraception was mandatory during the study. Patients
had to have been under continuous SC abatacept treat-
ment for at least 3 months before the start of the study
and remained under continuous synthetical DMARD
therapy throughout the study. Oral corticosteroids
(≤10 mg/day prednisone equivalent) were permitted with
stable dosing during the month before baseline and
throughout the study period. Patients who had failed more
than two biological DMARDs other than abatacept or
who had active uncontrolled disease, chronic infection, or
a history of cancer in the last 5 years, other than non-
melanoma skin cell cancers cured by local resection or
carcinoma in situ, were excluded from the study.
Assessments
The primary efficacy endpoint was the proportion (per-
centage) of subjects still in LDA (or in remission) on day
28; the proportions of patients in LDA on days 84 and
168 (versus baseline, when the IV abatacept infusion was
administered) were secondary endpoints. Change from
baseline evaluation of DAS-28 (ESR) score, health as-
sessment questionnaire disability index (HAQ-DI) [10],
and percentage of patients remaining on therapy with
SC abatacept on days 28, 84, and 168 were analyzed as
secondary endpoints. Treatment-emergent AEs and se-
vere AEs relating to the switch to IV abatacept and the
return to weekly SC abatacept were analyzed on days 28
and 168, respectively. Whether IV abatacept or tumor
necrosis factor (TNF) antagonist pre-exposition influ-
enced the occurrence of AEs or the evolving disease ac-
tivity was also analyzed.
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Statistical analyses
The data were exported from secuTrial (interActive Sys-
tems GmbH, Berlin, Germany) on December 19, 2014.
The statistical analysis was a per protocol (PP) analysis
for the efficacy endpoints and an intention-to-treat
(ITT) analysis for safety.
There were no missing data for the primary endpoint.
Thus, the PP analysis was equal to a complete case ana-
lysis. For the secondary endpoints, a complete case ana-
lysis was performed for continuous variables. The two
patients who dropped out of the study were calculated
as therapeutic failures for the analysis.
For quantitative variables, descriptive statistics were
employed. The primary endpoint was the proportion of
patients with DAS-28 of not more than 3.2. Correspond-
ing 95 % confidence intervals (CIs) for binomial prob-
abilities are also reported (Wilson method). IV abatacept
pre-exposed versus non-pre-exposed patients as well as
patients with TNF antagonist versus patients without
TNF antagonist pre-exposure were compared with a
Mann-Whitney U test for continuous variables and with
a Fisher’s exact test for binary variables. The change
from baseline for DAS-28 and the HAQ-DI throughout
the study period were compared by using linear mixed
models (with random intercept and slope) with baseline
as a predictor and time point as a covariate. Statistical
analyses were performed with Statistical Package for the
Social Sciences (SPSS) and the R programming language
(version 3.1.0, R CORE TEAM [2013]; R: A Language
and Environment for Statistical Computing; R Founda-
tion for Statistical Computing, Vienna, Austria; http://
www.R-project.org). The package Hmisc (Harrell, Frank
E. Jr., with contribution form Charles Dupont and many
others [2013]; Hmisc: Harrell Miscellaneous; R package
version 3.13-0; http://CRAN.R-project.org/package=H-
misc) was used to compute CIs for proportions, and the
package lme4 (Bates, Douglas, Maechler, Martin, Bolker,
Ben, Walker, Steven [2013]; lme4: Li near mixed-effects
models using Eigen and S4; R package version 1.0-5;
http://www.inside-r.org/packages/lme4/versions/1-0-5)
was used to compute linear mixed models.
Results
Patient characteristics and disposition
In total, 52 patients were included in the study (ITT). Three
patients did not fulfill one of the inclusion criteria (DAS-28
of not more than 3.2) but were included by the principal in-
vestigator’s decision. The reasons for not fulfilling all inclu-
sion criteria were transient ESR elevation in one case and
increased patient’s global assessment of disease activity in
another two, all of which quickly normalized between visit
1 and 2 (i.e., within 4 weeks), and all three patients were in
LDA during almost the complete follow-up. However, these
patients were excluded from the PP analysis. Fifty of the 52
patients completed the 24-week study. Patient demograph-
ics and baseline characteristics were similar in both analyses
(ITT and PP) and indicated low baseline disease activity
and longstanding disease (Table 1). One patient dropped
out on day 28 and one on day 84, the first because of a flare
and the second on the patient’s decision despite constant
LDA. Both patients were counted as therapeutic failures for
the analysis.
Clinical efficacy
In total, 46 out of 49 patients (PP analysis) were still in
LDA after 28 days (ITT: 49/52). Thus, the proportion of
Table 1 Demographical data (at baseline)
Intention to treat Per protocol
Number, number 52 49
Gender, female/male 31/21 29/20
Age, years 59.1 ± 10.8 59.3 ± 11.0
Body mass index, kg/cm 27.8 ± 5.3 27.8 ± 5.4
Disease duration, years 8.7 ± 8.2 8.3 ± 7.7
HAQ-DI, baseline 0.55 ± 0.66 0.58 ± 0.67
Tender joint count 68, mean ± SD 1.95 ± 2.97 2.11 ± 2.95
Swollen joint count 68, mean ± SD 0.55 ± 1.29 0.60 ± 1.30
Erythrocyte sedimentation rate, mm/h 11.37 ± 6.00 11.38 ± 7.0
C-reactive protein, mg/l 3.49 ± 2.00 6.28 ± 3.0
Patient’s global assessment of disease
activity (VAS 0–100)
16.97 ± 13.26 15.81 ± 17.90
Patient’s global assessment of pain
(VAS 0–100)
19.62 ± 16.61 18.05 ± 17.58
Physician’s global assessment of
disease activity (VAS 0–100)
10.98 ± 9.28 14.33 ± 7.45
DAS-28 1.73 ± 0.72 1.82 ± 0.80
Rheumatoid factor-positivea 62.0 % 63.8 %
ACPA-positivea 50.0 % 51.1 %
Erosive diseasea 58.3 % 55.5 %
Pre-exposed to IV abatacept 38.5 % 34.6 %
Pre-exposed to TNF antagonists 60.1 % 53.4 %
Pre-exposed to other biologic agents 28.8 % 26.9 %
Concomitant therapy
Leflunomide n = 20 n = 19
Leflunomide + hydroxychloroquine n = 1 n = 1
Methotrexateb n = 18 n = 16
Hydroxychloroquine n = 5 n = 5
Sulfasalazine n = 4 n = 4
Sulfasalazine + hydroxychloroquine n = 3 n = 3
Prednisolone dose or equivalent, mg/d 2.66 ± 3.25 2.82 ± 3.28
aMeasured on patients with data assessable
bMethotrexate was always applied in subcutaneous formulation
HAQ-DI Health assessment questionnaire disability Index, SD standard
deviation, ACPA anti-citrullinated peptide antibodies, VAS visual analog scale,
DAS-28 disease activity score in 28 joints
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patients with DAS-28 of not more than 3.2 as the pri-
mary endpoint was 93.3 % (95 % CI 83.5–97.9; Fig. 1a).
Two out of the three patients with a DAS-28 of more
than 3.2 on day 28 were back to LDA at the end of the
study (i.e., on day 168) without any additional interven-
tion. The average DAS-28 values were 1.73 (standard de-
viation (SD) ± 0.72) at baseline, 2.03 (SD ± 1.03) on day
28 and 1.96 (SD ± 0.97) at the end of the study (Fig. 1b).
Pre-exposition to IV abatacept (Fig. 1c) or TNF antago-
nists (Fig. 1d) did not significantly influence the average
DAS-28 or the proportion of patients retaining LDA.
Patient-reported outcome
The average HAQ-DI values were 0.55 (SD ± 0.66) at
baseline, 0.54 (SD ± 0.68) at day 28, and 0.56 (SD ± 0.66)
at the end of the study (Fig. 1e, PP analysis). Pre-
exposition to IV abatacept or TNF antagonists did not
significantly influence the average HAQ-DI 28 (data not
shown). The linear mixed model did not indicate any
significant effect of time on HAQ-DI (estimate −5.28 ×
10−5, 95 % CI −7.82 × 10−4–8.87 × 10−4).
Safety
Out of 52 patients (ITT), 39 patients had a total of 96
AEs with a maximum of seven AEs per patient; 67 % of
the AEs were judged by the treating physician as not to
be related, 5.2 % as unlikely, 25 % as possibly, 1 % as
probably, and 1 % as definitely related to IV abatacept as
the study drug. All AEs, which were possibly, probably,
or definitely related to study drug were of mild intensity.
No AEs of special interest (cancer, overdose, transmis-
sion of an infectious agent via the medical product, po-
tential drug-induced liver injury, allergic reactions, or
blood dyscryasis) were reported. Twenty percent of the
AEs occurred during the first 28 days after IV infusion
of abatacept. Pre-exposure to IV abatacept or TNF an-
tagonists did not influence the frequency of AEs.
In total, four serious AEs were described during the
study: nodule on the vocal cord, subcutaneous leg
edema, collapse at home, and depression. All serious
AEs resulted in a hospitalization and were resolved dur-
ing this hospitalization (Table 2).
Discussion
This prospective, open-label, 24-week study of abatacept
demonstrated for the first time in a controlled study set-
ting that switching from weekly SC to IV abatacept and
back is effective and safe and may be used to bridge
4 weeks in RA patients in DAS28-defined LDA or in
remission.
Reggia et al. [11] have described a loss of efficacy after
switching from IV to SC abatacept. A similar observation
Fig. 1 Disease activity per protocol. a The proportion of patients in low disease activity (LDA) was depicted with the 95 % confidence interval (CI)
as an error bar. The interval of the intravenous (IV) abatacept between days 0 and 28 is marked with a bar. Before and after this time frame, the
patient was treated with subcutaneous (SC) abatacept. b The mean disease activity score in 28 joints (DAS-28) was depicted for all patients with
the standard deviation (SD) as error bars. c The mean health assessment questionnaire disability index (HAQ-DI) was depicted for all patients with
the SD as error bars. d The mean DAS-28 was depicted for patients pre-exposed to tumor necrosis factor (TNF) antagonists (black) and not pre-exposed
(red) separately with the SD as error bars. e The mean DAS-28 was depicted for patients pre-exposed to IV abatacept (black) and not pre-exposed (red)
separately with the SD as error bars
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could not be made in our study, where the vast majority
of patients remained in LDA not only at the primary end-
point on day 28 but also 6 months after switching back
from IV to SC abatacept. There may be several reasons
explaining this discrepancy. In our study, all patients had
been pre-exposed to SC abatacept and were in stable
LDA or in remission already at the beginning of the
study, whereas in the setting of Reggia et al., patients
were automatically switched from continuous IV abata-
cept to the SC formulation. It has to be kept in mind that
the study by Reggia et al., in contrast to ours, was not a
prospective study but an observational retrospective
study and that minimal increases in DAS-28 could
already have met their internal definition of a flare. This
definition was not provided in their article. Similar main-
tenance of the good status LDA or remission after
switching from IV to SC abatacept was found by others
in the context of clinical trials [8] or in a case series [12].
This lack of a difference in clinical effectiveness in a drug
with two pharmaceutical formulations is to be expected,
in particular with regard to the previously reported non-
inferiority in efficacy and safety for IV and SC abatacept
in the ACQUIRE (Abatacept Comparison of Subcutane-
ous versus Intravenous in Inadequate Responders to
Methotrexate) study [6].
Importance of practical issues
The treatment of rheumatological patients while aim-
ing to treat to target and achieving LDA or remission
should also consider practical aspects of the patients’
daily lives. Patients, as is their natural right, try to
lead a life which is as normal as possible despite their
disease. Even though LDA or remission is the basis
for this, it has to be considered that reaching an arti-
ficial target such as a calculated pre-defined DAS-28
level should not intervene with the patients’ individ-
ual demands and perception of life. Administration of
only one IV dose may help patients on abatacept to
cover even longer periods of absence for vacations or
other reasons (e.g., business trips).
Safety
The safety profile was similar to that observed in previous
abatacept studies [2, 3, 6, 13]. Importantly, the rate of AEs
did not increase within the first 28 days after IV applica-
tion. The time interval permitted between the last SC dose
and the IV abatacept application during the study ranged
from 4 to 11 days. Whether shorter intervals between the
SC and IV application of abatacept may increase the AE
rate remains open but does not seem likely.
Limitations
The extent of abatacept’s contribution to the mainten-
ance of LDA or remission in the patients of our study
with longstanding disease and concomitant DMARD
therapy in all patients is uncertain. Only a randomized
placebo controlled study might have shown a difference
between the flare rate after a placebo and a verum IV
abatacept application.
Even though such as study has not been conducted so far,
there are some interesting observations in others. In the
AVERT (Assessing Very Early Rheumatoid arthritis Treat-
ment) study, early arthritis patients naïve to MTX were
treated with SC abatacept and MTX [14]. All therapies (aba-
tacept, MTX, and glucocorticosteroids) were stopped in pa-
tients reaching LDA. Within 4 weeks, the rate of patients in
remission dropped from 61.3 % to about 51 % (-16.8 % of
the patients in remission). In the ALLOW () trial, a tempor-
ary withdrawal of SC abatacept but not of MTX resulted in a
slight increase of DAS-28 after 3 months, followed by
complete recovery after reintroduction of abatacept [3].
All patients on MTX were treated with subcutaneously
which is supplied by the manufacturer in prefilled syrin-
ges and, contrary to SC abatacept, is stable at room
temperature for up to 2 years after manufacturing. Fra-
gility could still pose the same problems as for SC abata-
cept. Therefore, replacing SC with oral MTX could be
an option which was not investigated in our study.
The AE rate in total appears to be higher as compared
with other studies with SC abatacept. However, muscu-
loskeletal problems, including arthralgia and arthritis
Table 2 Adverse events: weeks 0 through 24
System Number Description
Musculoskeletal 31 Arthritis/arthralgia (15), back pain (4), unspecific pain (3) osteopenia/osteoporosis (3), morning stiffness (1),
tendovaginosis stenosans (1), plantar fascia pain (1), worsening fibromyalgia (1), tendinitis calcarea (1)
Infection 25 Upper airway infection (18), herpes labialis (2), fungi infection (2), fever (3)
Gastrointestinal 13 Vomiting (4), diarrhea (3), flatulence (1), diabetes mellitus (1), abdominal cramps (1), esophageal reflux (1),
aphthous ulcers (1), lip blisters (no herpes proven, 1)
Neuro-psychological 14 Patient falling (4), restless legs (1), neuropathy (1), reduced leg strength (1), fatigue (1), anxiety (1), dysesthesia (1),
depression (1), hyperventilation (1), involuntary movements (1), dizziness (1)
Other 7 Leg edema (2), polyp on vocal cord (2, same patient), hypokalemia (1), suspected claudicatio (1), vitamin D
deficiency (1),
Dermatological 6 Exanthema (2), hematoma (2), hair loss (1), red eye (1)
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(15.6 % of all AEs), counted as AEs. Furthermore, selec-
tion of few sites with known high-quality standards may
have led to a higher frequency of documented AEs. Im-
portantly, no AEs of special interest such as defined for
this study (cancer, overdose, transmission of an infectious
agent via the medicinal product, potential drug-induced
liver injury, allergic reactions, and blood dyscrasias) were
documented, and all serious AEs were resolved during in-
patient treatment.
Whether radiographic data would have been important
for this analysis is a disputable issue. In our opinion, the
follow-up was too short and the study would have re-
quired many more patients to be able to show adequate
changes during radiographic progression.
Conclusions
This study demonstrated the effectiveness and safety of
switching from SC to IV abatacept before a vacation or
business trip and then continuing with SC abatacept
4 weeks later. It is the first study to demonstrate this in a
prospective manner. In our view, it emphasizes the need
for both ways of abatacept administration. Whether this
may also be true for other biologic agents available in both
formulations remains open without further studies.
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